Table 3.

Differences in eGFRcys decline by race and APOL1 genotype

GroupNeGFRcys decline ml/min per 1.73 m2 (% per year)β coefficient (95%CI) eGFRcys (% ml/min per 1.73m2 per year)
Model 1Model 2Model 3
Comparison within blacks
Low-risk black11540.82RefRefRef
High-risk black1761.190.38a (0.13–0.63)0.38a (0.14–0.62)0.40a (0.17–0.64)
Comparison between whites and blacks
Low-risk black11540.820.26a (0.14–0.38)0.10 (–0.01–0.22)0.04 (–0.08–0.16)
High-risk black1761.190.64a (0.39–0.88)0.48a (0.24–0.72)0.45a (0.21–0.68)
  • Model 1 incorporated demographic variables (age, sex, visit, global ancestry); model 2 incorporated demographic and pathophysiologic variables (smoking, BMI, systolic BP, use of antihypertensive medications, and diabetes); model 3 incorporated demographic, pathophysiologic and socioeconomic variables (participant income, participant education, caretaker education, employment status, access to care indicators).

  • The beta coefficients indicate the direction and magnitude of GFR decline: positive β coefficients can be interpreted as % ml/min per 1.73 m2 faster decline. For example, compared with low-risk black persons, high-risk black persons declined by 0.40% ml/min per 1.73 m2 per year faster. eGFRcys, estimated GFR by cystatin C.

  • a P values <0.05.